Browsing tag:

latanoprost


Brimonidine Tartrate

Brimonidine Tartrate CAS No: 79570-19-7 Known for treating open-angle glaucoma, brimonidine tartrate is a safe and effective API for reducing pressure behind the eye. The medication allows better drainage of fluids to both relieve patient suffering and protect eyes from further damage. High-fluid pressure can cause anything from mild nerve damage to total blindness. However,[…]

Read More

As the most commonly prescribed treatment for glaucoma, Latanoprost has taken the pharmaceutical headlines by storm with the latest study data revelations. At the end of December 2014 The Lancet published remarkable study results indicating that the use of Latanoprost reduced the risk of glaucoma by over 50 percent when taken for two years’ time.[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service